Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Prelude Therapeutics Incorporated

Prelude Therapeutics is a precision oncology company developing innovative medicines for cancer patients, with a focus on creating first/best-in-class programs in clinical trials. The company is engaged in discovering, developing and commercializing target-specific treatments.

NASDAQ:PRLD

Prelude Therapeutics

Last Close

1.27

08/11 21:00

Market Cap

197.20M

Beta: 0.45

Volume Today

534.71K

Avg: 78.70K

PE Ratio

−1.89

PFCF: −2.00

locale

market

industry

website

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics